Bill Chapman

Christian Bozorth

Gloria Gaddy

Jim Desborough

Matthew Kress

- For the fiscal year ended July 31, 2025, **net product sales** increased by **$243,000** to **$2,198,000**, up from $1,955,000 in the prior fiscal year.  **[1006028_0001493152-25-020058_ex99-1.htm:0]** 
- The company reported a **net loss of ($2.4 million)** for fiscal year 2025, an improvement from a net loss of ($3.4 million) in fiscal year 2024, with **net loss per share at ($0.02)** compared to ($0.03) in the previous year.  **[1006028_0001493152-25-020058_ex99-1.htm:0]** 
- **Net cash used in operations** decreased to **($2.0 million)** for fiscal year 2025, down from ($2.5 million) in fiscal year 2024.  **[1006028_0001493152-25-020058_ex99-1.htm:0]** 
- PURE Bioscience expanded its core business by **14%** and developed a new membrane treatment solution for the dairy and beverage industries, while also expanding its distribution network through partnerships with Hydrite Chemical Company and Bonsai.  **[1006028_0001493152-25-020058_ex99-1.htm:0]** **[1006028_0001493152-25-020058_ex99-1.htm:1]** 
- Total liabilities increased to **$6,174,000** at July 31, 2025, from $3,682,000 at July 31, 2024, and the total stockholders' deficiency worsened to **($5,116,000)** from ($2,864,000) over the same period.  **[1006028_0001493152-25-020058_ex99-1.htm:4]**

PURE Bioscience Reports Fiscal Year 2025 Financial Results and Business Updates

- PURE Bioscience reported **net product sales of $2,198,000** for the fiscal year ended July 31, 2025, an increase from $1,955,000 in the prior fiscal year.  **[1006028_b6067ebc925b41e481e39c7b131a0bf7_0]** 
- The company's **net loss improved to ($2.4 million)**, or **($0.02) per share**, for fiscal year 2025, compared to a net loss of ($3.4 million), or ($0.03) per share, in fiscal year 2024.  **[1006028_b6067ebc925b41e481e39c7b131a0bf7_0]** 
- PURE Bioscience launched a **groundbreaking membrane treatment solution** for dairy and beverage producers and **expanded its distribution network** through new agreements with Hydrite Chemical Company and Bonsai.  **[1006028_b6067ebc925b41e481e39c7b131a0bf7_0]** **[1006028_b6067ebc925b41e481e39c7b131a0bf7_1]** 
- Net cash used in operations for fiscal year 2025 was **($2.0 million)**, an improvement from ($2.5 million) in fiscal year 2024.  **[1006028_b6067ebc925b41e481e39c7b131a0bf7_0]**

PURE BIOSCIENCE (PURE)